News | February 07, 2025
Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
Branded formulation business continues to perform well across domestic and export markets
Branded formulation business continues to perform well across domestic and export markets
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Cancer cases in India estimated to reach 1.57 million in 2025
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Subscribe To Our Newsletter & Stay Updated
